RxDoctor Payments Data

Hyeyoon Park

Adult Health · Flushing, NYNPI 1760840201

Payments from drug & device makers

$7,910in general payments, 2019–2025

Across 360 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$1K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$753
  • Regeneron Healthcare Solutions, Inc.$578
  • Pfizer$499
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$7,65297%
  • Education$2583%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,910 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$57,231
Medicare patients
201
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa25$495,767
Dupixent PenDupilumab83$304,626
Cosentyx Sensoready (2 Pens)Secukinumab16$125,507
OpzeluraRuxolitinib Phosphate38$77,295
AdbryTralokinumab-Ldrm20$71,661
Dupixent SyringeDupilumab16$60,904
XolairOmalizumab14$40,119
Tacrolimus159$34,530
VtamaTapinarof14$19,270
EucrisaCrisaborole16$15,079
Clobetasol Propionate172$11,407
Ammonium Lactate430$10,516
Ketoconazole459$6,926
CiclopiroxCiclopirox Olamine136$6,809
Halobetasol Propionate89$6,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$36$77,29538 claims
LEO Pharma Inc.Adbry$331$71,66120 claims
Dermavant Sciences, Inc.Vtama$292$19,27014 claims
PfizerEucrisa$499$15,07916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →